PARIS, March 6, 2020 /CNW/ - Nanalysis Scientific Corp. (Nanalysis, TSXV:NSCI, FRA:1N1) is joined by the Canadian ambassador to France, Ms. Isabelle Hudon at the Canadian Embassy in Paris to commemorate the formal closing of the Nanalysis-RS2D S.A.S. (RS2D) acquisition. The agreement was finalized March 3, 2020 in Strasbourg, France. Nanalysis met with the Canadian ambassador to France, Ms. Isabelle Hudon at the Canadian Embassy in Paris to commemorate the formal closing.
Over half of all trade between Canada and France is qualified as 'high-tech' by the government of Canada with a long-standing policy to accelerate the development of the domestic tech sector as well as to increase tech exports.
Ambassador Hudon said, "Canada's trading relationship with France has grown by over 25% since 2017 to more than $12B in annual bilateral trade. Small and medium sized enterprises (SMEs) have played a large part in that growth and are a key to continuing in this direction. I'm also very pleased to see deals like this that will benefit both countries and increase international cooperation.
Mr. Krakiwsky, founder and CEO of Nanalysis, added "We are fully committed to making this acquisition successful. We have seized a unique opportunity to combine incredibly talented people and innovative technology platforms to accelerate the growth of our businesses. We are confident that our efforts will result in smooth and effective integration, allowing the release of high-performance, innovative magnetic resonance tools that the market requires."
Remy Schimpf, now VP of Sales for Nanalysis, said "It's nice to take time to celebrate this milestone so we can begin to look ahead and execute the plan that Sean and I have crafted during our discussions over several years." Mr. Schimpf will play an important role in guiding the combined sales organization and continue to provide invaluable insights into the evolution of the technology platform.
Established in 2004 by Rémy Schimpf, RS2D is based in the Eurometropolis of Strasbourg, and employs 20 people. RS2D is a global leader in the design and sales of NMR and MRI electronics consoles and software. The CameleonTM electronics board is the world's best controller board for NMR and MRI consoles, and is sold as an OEM board to numerous manufacturers. The PulseTM electronics console contains CameleonTM board, but also consists of several other proprietary electronics boards and is operated using RS2D's SPINitTM software. The Pulse console is sold as a stand-alone product in high field NMR installations. The company has developed and sells an advanced software suite with PRimTM for MRI and SPINitTM for NMR. The company, with partners, has been a pioneer in preclinical imaging: For example, RS2D developed the first rodent MRI system in the world that has a superconducting magnet without the need for liquid cryogenic cooling. For more information, visit the RS2D website: https://www.rs2d.com.
Nanalysis trades on the TSX Venture Exchange (TSXV) in Canada with ticker symbol 'NSCI' and the Frankfurt exchange under the ticker symbol '1N1'. The company's business is what we term "MRI and NMR for industry". The company develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for laboratory and industrial markets. The NMReady-60™ was the first full-feature portable NMR spectrometer in a single compact enclosure requiring no liquid helium or any other cryogens. The company has followed-up that initial offering with new products and continues to have a strong innovation pipeline. Nanalysis recently announced that it has begun selling a 100MHz device in 2020. The Company's new device will be the most powerful and most advanced compact NMR device ever brought to market.
Nanalysis devices are used in many industries (oil and gas, chemical, mining, pharma, biotech, flavor and fragrances, agrochemicals, law enforcement, and more) as well as numerous government and university research labs around the world. The company continues to exploit new global market opportunities independently and with partners.
Notice regarding Forward Looking Statements and Legal Disclaimer
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipate", "continue", "estimate", "expect", "may", "would" occur. Forward looking statements in this news release includes but is not limited to statements and phrases such as "cutting edge", "world-class electronics technology", "best NMR/MRI technology platform in the world", and "as we usher in the next phase of NMR and MRI". These statements are only predictions of what we believe might happen. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Nanalysis Scientific Corp.
For further information: Sean Krakiwsky, CEO, Nanalysis Scientific Corp., T +1.587.436.1291